WATERTOWN, Mass. — Landmark Bio, LLC announced a new collaboration with Mass General Brigham to provide development and manufacturing support for cell and gene therapies originating within the health system. The agreement establishes a framework for advancing early-stage translational research through collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI), accelerating the progression of novel therapeutic candidates from the laboratory to clinical application.
“This collaboration underscores our shared mission to bring breakthrough therapies to patients faster,” said Ran Zheng, chief executive officer of Landmark Bio. “Working with the exceptional teams at the Mass General Brigham Gene and Cell Therapy Institute, we are excited to provide the infrastructure and expertise that can help translate cutting-edge science into real-world impact.”
“The GCTI exists to help realize the promise of cell and gene therapies developed by investigators across Mass General Brigham,” said Roger J. Hajjar, M.D., head of the Gene and Cell Therapy Institute at Mass General Brigham. “This collaboration with Landmark Bio reflects our commitment to translational science and working together with collaborators to move transformative therapies forward.”
The partnership is designed to streamline the early development and manufacturing of next-generation therapies by connecting Landmark Bio’s advanced biomanufacturing capabilities with Mass General Brigham’s extensive research network. Together, the organizations aim to accelerate the development of innovative treatments addressing unmet medical needs in cell and gene therapy.
